OUR TEAM

Leadership

Board Of Directors

LAURA BENJAMIN, PH.D.

Founder & CEO

LAURA BENJAMIN, PH.D.

CEO and Founder

Before starting the company in 2018, Laura was a Vice President in Oncology at Eli Lilly where she led cancer discovery and translational discovery teams in NY and Indianapolis. She worked closely with the clinical teams to support multiple clinical programs, most notably the ramucirumab program from Phase 2 to commercial launch in colorectal, gastric, and non-small cell lung cancers. Additionally, she helped build the cross-functional initiative to discover, test and advance biomarker development in oncology clinical trials across the portfolio. Prior to joining Lilly, Laura spent 10 years as a tenure track professor in the Department of Pathology at Harvard Medical School. During this time, she supported and mentored Ph.D. students, postdocs and medical students with NIH and foundation grants. When she left Harvard in 2009, Laura was an Associate Professor and was co-Director of the Vascular Biology Center at the Beth Israel Deaconess Medical Center. Both Laura’s postdoctoral work and academic research at Harvard focused on cellular and molecular mechanisms driving cancer, with a particular interest in the role of the microenvironment on cancer progression and response to targeted therapies. Laura received a B.A. in Biology from Barnard College, Columbia University and a Ph.D. in Molecular Biology from the University of Pennsylvania.

HAGOP YOUSSOUFIAN, M.D.

Chief Medical Officer

HAGOP YOUSSOUFIAN, M.D.

Chief Medical Officer

Dr. Youssoufian is a physician-scientist with more than 25 years of experience in drug development working with seed-stage ventures to multi-national biotech and pharmaceutical corporations. After a successful academic career as a clinician, teacher and NIH-funded investigator, he held increasingly senior roles in clinical and translational science at Bristol-Myers Squibb (Head of Experimental Medicine), Sanofi Aventis (Distinguished Scientist), ImClone (CMO), Ziopharm Oncology (President of R&D and CMO), Progenics (EVP of R&D), and BIND (CMO). He supported or led the development and approval of a number of medicines including Sprycel, Taxotere, Erbitux, Cyramza, Lartruvo and Copiktra. He is an elected member of the American Society for Clinical Investigation, the recipient of many national and international awards, and the author of more than 100 publications. He received a B.S. in biology from Boston College and M.Sc./M.D. from University of Massachusetts Medical School, followed by fellowships at Johns Hopkins, Harvard and MIT.

MATTHEW OSBORNE

Chief Financial Officer

MATTHEW OSBORNE

Chief Financial Officer

Matthew’s career includes 20+ years of biotechnology capital markets, strategic corporate finance and business operations experience that spans both industry and Wall Street. During this time, he led multiple equity financings providing companies the capital to grow through preclinical, clinical and commercial stages of development while driving the core strategic, financial, scientific, product, program, and corporate planning among all stakeholders, in addition to concluding multiple mergers and acquisitions. As a former Wall Street equity biotechnology sell-side analyst, he launched several biotech IP0s, and analyzed the development of several blockbuster drugs across multiple therapeutic areas and modalities. Mr. Osborne most recently served as Chief Financial Officer of Unum Therapeutics, previously as VP of Corporate Affairs, Communications and Investor Relations at Voyager Therapeutics, as VP of Investor Relations and Corporate Communications at Synageva BioPharma (acquired by Alexion), Global Head of Investor relations at Shire Plc (acquired by Takeda) and as Investor Relations at Vertex Pharmaceuticals. Prior to his industry roles, Matthew served as a sell-side analyst covering the biotechnology sector at Lazard Capital Markets and Leerink Swann (SVB Leerink). He received an M.B.A. from the D’Amore-McKim School of Business at Northeastern University and a B.S. in Biology from Syracuse University.

DAVID MALEK

Interim Chief Business Officer

DAVID MALEK

Interim Chief Business Officer

Prior to joining Oncologie, David served as the Chief Business Officer of BioLineRx, an oncology drug development company, for seven years, during which he was responsible for building the company’s portfolio and partnering with several leading oncology companies. Before joining BioLineRx, he served at Sanofi-Aventis in a number of management positions, including Marketing, Mergers and Acquisitions, Finance and Business Development, where he focused on oncology. David received an MBA from the Tuck Business School at Dartmouth University and a B.A. in statistics and political science from the University of Haifa.

KERRY CULM-MERDEK, PH.D.

Vice President, Clinical Development

KERRY CULM-MERDEK, PH.D.

Vice President, Clinical Development

Kerry brings over 15 years of clinical drug development expertise and experience in small molecule and therapeutic protein development in rare disease and oncology indications including Head of Clinical Pharmacology and Quantitative Bioanalytics at ImmunoGen Inc., where she was responsible for clinical pharmacology strategy for global clinical and preclinical development of oncology therapies. Prior to joining ImmunoGen, Kerry spent 13 years at Sanofi Genzyme, most recently serving as a Global Project Head, where she led the therapy project teams for Fabry disease, Gaucher disease type 3 and multiple gangliosidosis/galatosialidosis indications. Kerry received a B.S. in Biochemical Pharmacology from the State University of New York at Buffalo. She received a Ph.D. in Pharmacology and Experimental Therapeutics at Tufts University School of Medicine.

JONATHAN T. GRAVES

Head of Finance

JONATHAN T. GRAVES

Head of Finance

Jon has over 20 years of extensive experience in financial controllership, planning and analysis in the healthcare industry. Prior to joining Oncologie, Jon served as Vice President of Financial Operations at Corindus Vascular Robotics, Inc., a publicly traded global technology leader in robotic-assisted vascular interventions (acquired by Siemens Healthineers Company in 2019). Previously, Jon served as Controller of the North American division of Swedish Orphan Biovitrum AB, an international, publicly traded rare disease company, where he was responsible for the oversight of the finance and accounting functions for North America’s product sales. Prior to that, Jonathan served for ten years at Thermo Fisher Scientific in various finance leadership roles, most recently as Controller of a global business unit within the Portable Analytical Instruments Division and earlier in his career, served as Experienced Senior at Arthur Andersen LLP. Jonathan received a B.S. in Accounting from Providence College and is a Certified Public Accountant.

Celia Harrison, Ph.D., J.D.

Head of Legal

Celia Harrison, Ph.D., J.D.

Head of Legal

Celia brings 18 years of relevant legal and clinical experience acquired from working in the biotechnology industry, private practice and clinical research. Prior to joining Oncologie, Celia was Senior Attorney at Seres Therapeutics, Inc., where she had responsibility for legal matters including intellectual property and contract agreements to support research and development, clinical operations, manufacturing and information technology. Before joining Seres Therapeutics, Celia was the solo practitioner at the Harrison Law Office, where she specialized in U.S. patent applications in the biochemical, chemical and medical device arts as well as in patent prosecution. After completing her legal studies, Celia was a Patent Associate at Greenberg Traurig where she conducted domestic and foreign patent prosecution, licensing and intellectual property due diligence in licensing ventures and mergers and acquisitions. Earlier in her career, Celia spent eight years as a Scientist at the Boston Biomedical Research Institute and began her career as a post-doctoral fellow at the Rockefeller University, Howard Hughes Medical Institute. Celia continues to serve as Research Assistant Professor in the Department of Biochemistry at the Tufts University School of Medicine, a post she has held since 2009. Celia received a B.S. in Biology from Pacific Lutheran University, a Ph.D. in Molecular and Cell Biology from the University of California Berkeley and a J.D. from Boston College Law School.

SUSAN MACINTYRE

Head of Global
Clinical Operations

SUSAN MACINTYRE

Head of Global
Clinical Operations

Susan brings 25 years of experience in all aspects of clinical operations and study management including execution of Phase 1 through Phase 4 clinical trials. Prior to joining Oncologie, Susan served as Senior Director of Clinical Operations at Beyond Spring Inc., where she managed all strategic and tactical aspects of clinical trial execution and was responsible for operation the design, delivery and financial management of Beyond Spring’s global clinical oncology trials. Prior to that, Susan was Director, Clinical Operations, Oncology, at Daiichi Sankyo Inc., where she was responsible for all aspects of clinical operations resource management within the oncology therapeutic areas, including oversight of biomarker testing and implementation of investigational assays and previously, as Director of Clinical Operations (Oncology) at Taiho Pharma U.S. Susan began her career as a registered nurse at Pennsylvania Hospital and Riverside Hospital. She received a BSN from the University of the State of New York and a Diploma in Nursing and Associates degree at Frankford Hospital School of Nursing and Pennsylvania State University.

WILLIAM MCDONALD, PH.D.

Vice President, Chemisty, Manufacturing and Controls

WILLIAM MCDONALD, PH.D.

Vice President, Chemisty, Manufacturing and Controls

Bill brings more than 20 years of experience in process development and the manufacturing of antibodies, recombinant enzymes, antigens, antibody targets, viral vectors and vaccines. Prior to joining Oncologie, Bill served as Vice President, CMC at Contrafect Corporation where he was responsible for all CMC activities for Contrafect’s novel biologics platform of anti-microbial therapies. Previously, Bill served as Executive Director and Manufacturing Site Head at Celldex Therapeutics, Inc., where he oversaw the Fall River GMP manufacturing facility and was responsible for internal manufacturing of all early clinical stage biologics. Bill also held roles of increasing responsibility at Syngeva BioPharma Corp. (acquired by Alexion Pharmaceuticals, Inc. in 2015), including Senior Director of Process Development. He also previously served as Head of Process Science at Pfizer, Inc., Director of Antigen Production at Genocea Biosciences Inc. and Director of Biochemistry at VaxInnate Corporation. Within the scope of technical operations, he has supported the development and manufacture of several approved biologics including Kanuma, Soliris and Strensiq. Bill received a B.S. in Microbiology from the University of Florida and received a Ph.D. in Molecular Biology at Cornell University.

SARAH WANG

Head of Business Operations and Investor Relations, Oncologie’s China Affiliate (Ding Hang)

SARAH WANG

Head of Business Operations and Investor Relations, Oncologie’s China Affiliate (Ding Hang)

Prior to joining Oncologie, Sarah was Vice President at Pivotal bioVentures Partners, a venture capital firm focused on venture building in China’s life sciences industry, where she successfully invested in, incubated and managed portfolio companies in immuno-oncology and biosimilar areas, led investment execution and due diligence processes, term negotiation and finalization. Previously, she served as Vice President at I-Bridge Capital, a venture capital firm focused on China’s healthcare industry, where she successfully raised capital for the I-Bridge RMB fund I, additional capital for the I-Bridge USD fund I, and managed two portfolio companies in the cell therapy and medical device areas. Sarah served in the Life Science Group at KPCB China, a firm specializing in investment from incubation. Sarah began her career as a Scientist, Chemistry Department and in Business Development at Hutchison MediPharma, a pioneer biotech company in China dedicated to drug innovation. Sarah received a B.S. in Applied Chemistry, a B.A. in Business Administration and an M.Sc. in Organic Chemistry from Shanghai University. She received an M.B.A. from Nanyang Technological University.

REBECCA WOLFE

Vice President, Business Operations and Program Management

REBECCA WOLFE

Vice President, Business Operations and Program Management

An experienced leader, Becky is responsible for the global strategy and execution of cross-functional operations and program management related to drug development and business growth. Prior to joining Oncologie, Becky served in multiple roles of increasing responsibility for almost 20 years at Eli Lilly & Co., most recently as Director, Clinical Operations Implementation, where she was responsible for the global implementation of the Simplicity Clinical Trial Management System for site monitoring and central monitoring services across the company. Prior experience at Eli Lilly include sales, clinical trial management, clinical research monitoring and she also earned a Black Belt in Six Sigma. Becky began her career as a Clinical Dietitian at Brigham and Women’s Hospital. Becky received a B.S. in Nutritional Sciences from the University of New Hampshire and is a registered dietitian with the American Dietetic Association.

SIMON ZHANG, M.D.

General Manager and Vice President, Oncologie’s China Affiliate (Ding Hang)

SIMON ZHANG, M.D.

General Manager and Vice President, Oncologie’s China Affiliate (Ding Hang)

Prior joining Oncologie, Simon was the General Manager at Oxford Immunotec (Shanghai) Medical Device Co., Ltd., responsible for the establishment and execution on business operations for China, Taiwan and Hong Kong by engaging with professional and government organizations, identifying and analyzing business development opportunities and overseeing budgets and forecasts. Additionally, Simon served as Vice President of International Sales at Micropoint Bioscience Inc. and Vice President, Sales at Micropoint Biotech Ltd., where he led the commercial operations for diagnostic products for cardiovascular and infectious diseases in China, Asia, Europe and Middle East. Simon held additional roles with increasing responsibilities at Response Biomedical Corp., Pharmacia Diagnostics AB, Marrion Merrel Dow China and Eli Lilly Asia Inc. Prior to joining the industry, Simon served as a Physician in the Department of Internal Medicine, Xuan Wu Hospital, Capital University of Medical Sciences, where he completed his residency. Simon received his M.D. from Capital University of Medical Science and competed additional training in the Immunology Division, Institute of Medical Research, General Hospital of Army and the Institute of Pharmacology and Toxicology at the Academy of Military Medical Science. He is an elected member of the European Academy of Allergy & Clinical Immunology (EAACI).

COLLEEN MOCKBEE

Interim Head of Regulatory Affairs

COLLEEN MOCKBEE

Interim Head of Regulatory Affairs

Prior to joining Oncologie, Colleen served as Partner Therapeutics’ Chief Development Officer and Head of Regulatory and Quality. Before her move to biotech, Colleen established a distinguished career at Eli Lilly and Company spanning 20 years in oncology drug development where she held leadership roles in global regulatory, and health outcomes. Colleen’s final role at Lilly was as Verzenio global product development leader where she combined innovation with speed and empowered her team to create and execute a development strategy that led to the approval and launch of Verzenio for metastatic breast cancer, as well as the first positive early stage breast cancer study for a CDK 4&6 inhibitor. She received her B.S. in Chemistry, B.S. in Pharmacy from Butler University and an MBA from Purdue’s Krannert School of Business in 2016.

Peter Bisgaard

Chairman of the Board and Managing Director, Nan Fung Life Sciences and Pivotal Bioventures

Peter Bisgaard

Chairman of the Board and Managing Director, Nan Fung Life Sciences and Pivotal Bioventures

Peter Bisgaard joined Nan Fung Life Sciences as Managing Director in 2017. He has 20+ years of experience investing in biotech, medtech, diagnostics and research tools. Prior to joining Nan Fung Life Sciences, Peter was a senior team member of Novo Ventures (US) Inc. As part of the senior team, he was responsible for overall investment and portfolio strategy with special responsibility for the ongoing development of Novo Ventures in the US. Peter joined Novo Ventures in 2001 in Denmark. Prior to Novo Ventures he was with McKinsey & Co.’s Corporate Finance and Strategy Practice. Peter is the member of —or has been a member of— the Board of Directors of a number of public and private biotech, medtech, diagnostics and research tools companies including RA Pharmaceuticals (NASDAQ:RARX), Nevro Corp (NYSE:NVRO), Alder Biotherapeutics (NASDAQ:ALDR), Otonomy (NASDAQ:OTIC), HTG Molecular Diagnostics (NASDAQ:HTGM), Eargo Inc, Engrail therapeutics, Maplight Therapeutics, Entasis Therapeutics, Bolt Therapeutics and Inozyme Inc. Peter has an M.Sc. in Engineering from the Technical University of Denmark and has a post graduate degree in Mathematical Modeling in Economics by the European Consortium for Mathematics in the Industry.

Laura Benjamin, Ph.D.

CEO and Founder, Oncologie, LTD

Laura Benjamin, Ph.D.

CEO and Founder, Oncologie, LTD

Before starting the company in 2018, Laura was a Vice President in Oncology at Eli Lilly where she led cancer discovery and translational discovery teams in NY and Indianapolis. She worked closely with the clinical teams to support multiple clinical programs, most notably the ramucirumab program from Phase 2 to commercial launch in colorectal, gastric, and non-small cell lung cancers. Additionally, she helped build the cross-functional initiative to discover, test and advance biomarker development in oncology clinical trials across the portfolio. Prior to joining Lilly, Laura spent 10 years as a tenure track professor in the Department of Pathology at Harvard Medical School. During this time, she supported and mentored Ph.D. students, postdocs and medical students with NIH and foundation grants. When she left Harvard in 2009, Laura was an Associate Professor and was co-Director of the Vascular Biology Center at the Beth Israel Deaconess Medical Center. Both Laura’s postdoctoral work and academic research at Harvard focused on cellular and molecular mechanisms driving cancer, with a particular interest in the role of the microenvironment on cancer progression and response to targeted therapies. Laura received a B.A. in Biology from Barnard College, Columbia University and a Ph.D. in Molecular Biology from the University of Pennsylvania.

Vincent Cheung

Chairman, Nan Fung Life Sciences

Vincent Cheung

Chairman, Nan Fung Life Sciences

Vincent is the Chairman of Nan Fung Life Sciences. He founded Pivotal bioVenture Partners in 2017 and Pivotal bioVenture Partners China in 2018. Vincent is also the Managing Director and the Chief Operating Officer of the Nan Fung Group, responsible for the Group’s strategic development as well as overall operations. Prior to joining Nan Fung Group in 2009, Vincent had extensive experiences in the financial sector. He was Vice President of Barclays Capital Asia Limited and Citigroup Global Markets Asia Limited. He has served on the boards of several public and private companies in both biotech sector and real estate sector.

Mr. Cheung graduated with honors in Molecular and Cell Biology from the University of California, Berkeley.

James Huang

Founding Managing Partner, Panacea Healthcare Venture and Managing Partner, KPCB China

James Huang

Founding Managing Partner, Panacea Healthcare Venture and Managing Partner, KPCB China

James Huang is Founding Managing Partner of Panacea Healthcare Venture Capital with over 30 years in the healthcare sector as a successful entrepreneur、nvestor and an opinion leader in Venture Capital healthcare sector in China. James is also managing partner of Kleiner Perkins Caufield & Byers China. He joined the firm in 2011 and focuses on the firm’s life sciences practice. His main investment interests are innovation around China’s growing healthcare markets and helping entrepreneurs build companies. Prior to this, James was a Managing Partner at Vivo Ventures, a Venture Capital firm specializing in life sciences investments. Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson). James is Chairman of Board at Kindstar Global, JHL Biotech and XW Laboratory and Director at GenScript, ChiralQuest, Zenesis, CVie Therapeutics, CASI and Omni Pharmaceuticals.

James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.

Yunjoon Kim, DVM

Managing Director, Korea Investments Partners Co., Ltd

Yunjoon Kim, DVM

Managing Director, Korea Investments Partners Co., Ltd

Mr. Yunjoon Kim is a managing director of Korea Investment Partners Co.,Ltd (KIP), a leading venture capital and private equity firm managing over 50 funds globally. Since 2014, Yunjoon had extensive investment experiences in the biotechnology and healthcare sectors at KIP. He has been a key operational personnel at Global Pharmaceutical PE Fund in Korea, a founder of the ABL Bio (Immuno-oncology), SCM Lifescience (Cell therapy), and served as a Board member of Genome & Company (Microbiome).

Before joining KIP, Yunjoon worked at KHIDI (Korea Health Industry Development Institute, Governmental Affiliate) as a Senior Researcher supporting the technology commercialization (including global partnership) of Korea Bio-Healthcare companies. Previously, at Novartis, he was responsible for the Novartis Venture Korea Fund, In-licensing, Research Collaboration (R&D alliance), and with building up the strategic alliance, in-licensing, any business opportunities aligned the corporate strategy.

He joined Novartis Korea as Medical Scientific Liaison Officer, Clinical Development & Medical Affairs at 2007 in Korea. And he moved to Research Alliance Officer Position, in Strategic Planning & Partnering department at 2009. Before joining the Novartis Korea, he worked Pfizer Korea as a Professional Medical Representative, and Clinical Research Associate since 2003. He received a Masters in Public Health from Yonsei University and completed graduate coursework at the College of Pharmacy at Sungkyunkwan University.